

Fig. 6. (b) Affordability analysis compared with QIM

The cost-effectiveness of the Dynamic Functional Radiogenomics Integration Framework (DFRIF) in the context of individualized cancer care is an important consideration. The cost-effectiveness of DFRIF involves a number of factors that affect hospitals, patients, and the healthcare industry as a whole. DFRIF's initial cost-effectiveness is tied to the one-time expenditure needed to put it into action. Among these are investments in state-of-the-art imaging technology, new computer programs, and the education of medical professionals. For DFRIF to continue to be financially sustainable for healthcare institutions, it is crucial to find a happy medium between these upfront expenditures and the expected long-term advantages. Maintenance of hardware, software, and personnel required to run DFRIF effectively are ongoing expenses. Determining the cost-effectiveness of the framework requires weighing its operating costs against the benefits it provides in terms of better patient outcomes and fewer healthcare issues. The potential for long-term savings in healthcare expenditures is a major contributor to DFRIF's cost-effectiveness. DFRIF can reduce the risk of treatment-related problems, hospital length of stay, and drug costs by facilitating more precise planning and individualized interventions. It's not easy to put a number on these savings, they can have a major impact on healthcare budgets and patient bills. To be cost-effective, DFRIF must not put an undue financial burden on people who are already struggling to pay for their cancer care. It's crucial to make sure that everyone, regardless of their socioeconomic level, has equal access to healthcare appreciations to the framework. In the end, determining whether or not DFRIF is financially feasible requires doing a thorough cost-benefit analysis. The costs of adoption and ongoing maintenance must be weighed against the potential savings in healthcare expenditures and other positive outcomes such as better patient outcomes and fewer treatment problems. Careful consideration of these issues will help those with a stake in healthcare decide if DFRIF is a feasible and affordable option in the quest for customized cancer treatment. Figure 6(a) provides a direct comparison between the Dynamic Functional Radiogenomics Integration Framework (DFRIF) and an Affordability Analysis, emphasizing the positive influence the framework has on healthcare cost-effectiveness and accessibility. Figure 6(b) displays a comparison of Affordability Analysis and Quantitative Imaging Methods (QIM), providing insights into how QIM affects the cost-effectiveness of cancer treatment by taking into account patients' and healthcare systems' respective budgets. By comparing DFRIF and QIM, these visualizations teach healthcare decision-makers and stakeholders on the relative contributions of these two factors to the affordability of innovative cancer care solutions [18].

The results of this in-depth analysis reveal DFRIF to be a potent and flexible instrument that can improve both customer happiness and cost-effectiveness in the quest for personalised cancer therapy. Its significance attests to the dedication to providing high-quality care and easily accessible options for people with cancer.

CONCLUSION

When applied to the practice of cancer medicine, Quantitative Imaging Methods (QIM) represent a paradigm change that could have far-reaching consequences. QIM has been fundamental in bringing in a new era of accuracy, data-driven insights, and individualized treatment. QIM allows clinicians to uncover each patient's unique illness profile and develop individualized treatment plans by delving deeply into the complex terrain of cancer with statistical rigor and precision. However, there are obstacles on the road to QIM's widespread adoption in clinical practice. QIM's computational difficulties, need for standardization and seamless data integration, and other challenges require collaborative efforts and creative solutions. The proposed

Dynamic Functional Radiogenomics Integration Framework (DFRIF) provides a glimmer of hope in this regard by providing a mechanism to improve treatment planning via a finer appreciation of tumor morphology, heterogeneity, and treatment response. QIM's greatest strength is in its potential to bring in a new era of highly personalized cancer care. QIM improves the quality of care by tailoring treatments to each individual patient's cancer with the goal to reduce the likelihood of harmful side effects while increasing the likelihood of positive ones. In addition, QIM has applications beyond the realm of treatment strategy. Included in this all-encompassing method of cancer care are prognostic modeling, non-invasive monitoring, and early detection. By including simulation analyses, researchers may additionally assess the effect of QIM on patient happiness, resource allocation, and affordability, additionally offer helpful insights to healthcare practitioners and policymakers. Together, the integration of data and computer analysis provide physicians with unparalleled precision in navigating the complex landscape of cancer, allowing for a more targeted, efficient, and hopeful road to recovery for patients. QIM is a guiding light on this path, showing the way to more efficient, customized cancer treatment.

Maintaining DFRIF affordable for hospitals and available to people of all socioeconomic backgrounds is of utmost importance. Determining the framework's overall economic feasibility requires a careful balancing of costs and benefits through in-depth cost-benefit assessments. Integrating and growing DFRIF within the landscape of personalised cancer treatment is guided by the congruent principles of customer happiness and affordability analyses. DFRIF aims to fulfil its promise of better results and enhanced quality of life for cancer patients by placing a premium on patient well-being and providing financial accessibility.

1. Rogers W, Thulasi Seetha S, Refaee TA, Lieverse RI, Granzier RW, et al. Radiomics: from qualitative to quantitative imaging. Br J Radiol. 2020;93.
2. Ibrahim A, Primakov S, Beuque M, Woodruff HC, Halilaj I, Wu G, et al. Radiomics for precision medicine: Current challenges, future prospects, and the proposal of a new framework. Methods. 2021;188:20-29.
3. Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, Felli E, Saviano A, et al. Radiomics in hepatocellular carcinoma: a quantitative review. Hepatol Int. 2019;13:546-559.
4. Park JE, Park SY, Kim HJ, Kim HS. Reproducibility and generalizability in radiomics modeling: possible strategies in radiologic and statistical perspectives. Korean J Radiol. 2019;20:1124-1137.
5. Traverso A, Kazmierski M, Shi Z, Kalendralis P, Welch M, et al. Stability of radiomic features of apparent diffusion coefficient (ADC) maps for locally advanced rectal cancer in response to image pre-processing. Phys Med. 2019;61:44-51.
6. Papanikolaou N, Matos C, Koh DM. How to develop a meaningful radiomic signature for clinical use in oncologic patients. Cancer Imaging. 2020;20:1-10.
7. Liu Z, Wang S, Dong D, Wei J, Fang C, et al. The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges. Theranostics. 2019;9:1303.
8. Yang W, Warrington NM, Taylor SJ, Whitmire P, Carrasco E, et al. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci Transl Med. 2019;11:5253.
9. Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Călin AM, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30:998-1004.
10. Liu Z, Li Z, Qu J, Zhang R, Zhou X, et al. Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res. 2019;25:3538-3547.
11. Scapicchio C, Gabelloni M, Barucci A, Cioni D, Saba L, et al. A deep look into radiomics. Radiol Med. 2021;126:1296-1311.
12. Chetan MR, Gleeson FV. Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives. Eur Radiol. 2021;31:1049-1058.
13. Shukla-Dave A, Obuchowski NA, Chenevert TL, Jambawalikar S, Schwartz LH, et al. Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging. 2019;49:101-121.
14. Kooreman ES, van Houdt PJ, Nowee ME, van Pelt VW, Tijssen RH, et al. Feasibility and accuracy of quantitative imaging on a 1.5 T MR-linear accelerator. Radiother Oncol. 2019;133:156-162.
15. Hagiwara A, Fujita S, Ohno Y, Aoki S. Variability and standardization of quantitative imaging: monoparametric to multiparametric quantification, radiomics, and artificial intelligence. Invest Radiol. 2020;55:601.
16. Zhang Y, Lu D, Gao M, Lai M, Lin J, et al. Quantitative imaging of anion exchange kinetics in halide perovskites. Proc Natl Acad Sci. 2019;116:12648-12653.
17. Avanzo M, Wei L, Stancanello J, Vallieres M, Rao A, Morin O, et al. Machine and deep learning methods for radiomics. Med Phys. 2020;47:185-202.
18. Kobayashi N, Morisaki S, Atsumi N, Yamamoto S. Quantitative Non Functional Requirements evaluation using softgoal weight. J Internet Serv Inf Secur. 2016;6:37-46.